Jerusalem, Israel, September 18, 2017 – Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced the closing of a $8 million Series B equity financing round.

The financing was led by KIP Global Pharma Private Equity Fund, and HBL, a life-sciences investment company. Following the closing, KIP will has appointed two new members to the Enlivex board of directors.

Shai Novik, Chairman of Enlivex, commented, “We are pleased to welcome KIP as a significant shareholder. KIP, which is the largest Venture Capital fund in Korea, brings to the table a precedent track record of success in the Korean Venture Capital market with specific domain expertise in the pharmaceutical sector. We look forward to a fruitful cooperation, building shareholder value together”.

Sangwoo Lee, Executive Director of the Investment Department & Head of U.S. Branch at Korea Investment Partners Co. Ltd, commented: “this is our second investment in the bio-tech space in Israel. We are truly excited about the potential of Enlivex to effect a change in the space of immune-therapy”.


Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.  For more information, visit

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of ALLOCETRA™ programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA™ product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.


Shachar Shlosberger, CFO

Enlivex Therapeutics, Ltd.